2-(substituted ethynyl)quinoline derivatives as mGLUr5 antagonists

A pharmaceutical composition for treating mGluR5 receptor-mediated diseases, which comprises a compound selected from the group consisting of 2-(substituted ethynyl)quinoline derivatives represented by the following Formula 1 and pharmaceutically acceptable salts thereof as an active ingredient

• wherein Ar is an aryl or a heteroaryl group selected from the group comprised of phenyl and pyrimidinyl, wherein the aryl or heteroaryl group being unsubstituted or substituted with one to three substituents selected from the group consisting of halo, cyano, C1-C10 alkyl, and C1-C10 alkoxy;
• or Ar is a pyridinyl being substituted with one to three substituents selected from the group comprised of halo, cyano, C1-C10 alkyl, and C1-C10 alkoxy;
• or Ar is an unsubstituted pyridinyl having N portion in the 3rd position;
• and
• R1 is a hydrogen atom, a halogen atom, a hydroxyl group, C1-C10 alkyl, C1-C10 alkoxy, or C1-C10 alkyl carbonate,
• wherein the mGluR5 receptor-mediated disease is selected from the group consisting of Alzheimer's disease, senile dementia, Parkinson's disease, L-DOPA-induced dyskinesia, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile X syndrome, autism, migraine and gastroesophageal reflux disease (GERD).